Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
US Market
Holding TRDA?
Track your performance easily

Entrada Therapeutics Inc (TRDA) Income Statement

72 Followers

Entrada Therapeutics Inc Income Statement

Last quarter (Q2 2024), Entrada Therapeutics Inc's total revenue was $94.69M, an increase of 421.16% from the same quarter last year. In Q2, Entrada Therapeutics Inc's net income was $55.03M. See Entrada Therapeutics Inc’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 239.40M$ 129.01M--$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
$ 239.40M$ 129.01M----
Operating Expense
$ 145.94M$ 132.18M$ 97.25M$ -51.13M$ 26.67M$ 11.82M
Operating Income
$ 93.45M$ -3.16M$ -97.25M$ -51.13M$ -26.67M$ -11.82M
Net Non Operating Interest Income Expense
----$ 144.00K$ 451.00K
Other Income Expense
$ -20.42M$ -15.22M$ -2.63M$ 31.00K-$ 6.27M
Pretax Income
$ 175.88M$ 12.06M$ -94.62M$ -51.16M$ -26.52M$ -5.10M
Tax Provision
$ 5.97M$ 18.70M----
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 122.51M$ -6.68M$ -94.62M$ -51.16M$ -26.52M$ -5.10M
Basic EPS
$ 3.09$ -0.20$ -3.02$ -8.16$ -1.30$ -0.25
Diluted EPS
$ 2.95$ -0.20$ -3.02$ -8.16$ -1.30$ -0.25
Basic Average Shares
$ 134.34M$ 33.05M$ 31.29M$ 6.27M$ 20.48M$ 20.48M
Diluted Average Shares
$ 136.96M$ 33.05M$ 31.29M$ 6.27M$ 20.48M$ 20.48M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 145.94M$ 132.18M$ 97.25M$ -51.13M$ 26.67M$ 11.82M
Net Income From Continuing And Discontinued Operation
$ 104.44M$ -6.68M$ -94.62M$ -51.16M$ -26.52M$ -5.10M
Normalized Income
$ 131.37M$ 9.52M--$ -26.52M$ -5.10M
Interest Expense
------
EBIT
$ 119.97M$ 12.06M$ -94.62M$ -51.16M$ -26.67M$ -11.82M
EBITDA
$ 123.53M$ 9.08M$ -92.56M$ -50.06M$ -26.34M$ -11.72M
Currency in USD

Entrada Therapeutics Inc Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis